Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17643421 | 0.88 | EPHX2 (0.40) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL6631486 | 0.88 | EPHX2 (0.40) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL2379111 | 0.84 | EPHX2 (0.42) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL83783 | 0.84 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL27183 | 0.84 | ALDH1A1 (0.56) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL329321 | 0.81 | CYP1A2 (0.52) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL16727358 | 0.80 | EPHX2 (0.38) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL15431463 | 0.80 | EPHX2 (0.38) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL11850495 | 0.79 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL4550276 | 0.79 | SMN1; SMN2 (0.52) | CYP1A2TDP1EPHX2EPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155550-B2 | Histone deacetylase inhibitors and methods of use thereof | Reaction Biology Corporation (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190270744-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GOLUB CAPITAL LLC, AS COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155550-B2 | Histone deacetylase inhibitors and methods of use thereof | HDAC5, HDAC1, HDAC2 | CYP1A2 4503/4885TDP1 643/4885EPHX2 1700/4885 |
| US-20190270744-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | HDAC5, HDAC1, HDAC2 | CYP1A2 4503/4885TDP1 643/4885EPHX2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.